JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hosokawa, M.
Right arrow Articles by Seino, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hosokawa, M.
Right arrow Articles by Seino, Y.

Vol. 290, Issue 3, 1080-1084, September 1999

Troglitazone Inhibits Bicarbonate Secretion in Rat and Human Duodenum1

M. Hosokawa, H. Tsukada, K. Fukuda, M. Oya, M. Onomura, H. Nakamura, M. Kodama, Y. Yamada and Y. Seino

Department of Metabolism and Clinical Nutrition, Faculty of Medicine, Kyoto University, Kyoto, Japan

Troglitazone is a new, orally effective antidiabetic agent that decreases plasma glucose in obese patients with non-insulin-dependent diabetes mellitus. Unfortunately, troglitazone also has a propensity to cause edema. This study was designed to determine how troglitazone affects intestinal ion transport and water absorption. Short circuit current (Isc) was measured in rat and human duodenal mucosa in Ussing chambers. Five minutes later, the serosal addition of troglitazone caused Isc to decrease gradually, and after 50 min, Isc reached the peak of decrease. EC50 values and maximum response to Isc in rat and human mucosa were 8.4 and 8.7 µM and 8.56 ± 1.0 and 8.00 ± 2.0 µA/cm2, respectively. In an HCO3-/CO2-free system, the decrease in Isc caused by troglitazone was 1.31 ± 0.83 µA/cm2. When 10 mM acetazolamide was preadministered, the small decrease in Isc evoked by troglitazone (20 µM) was 4.56 ± 0.22 µA/cm2, whereas the preadministration of 100 µM amiloride and 100 nM tetrodotoxin did not influence the decrease in Isc evoked by troglitazone. The serosal preadministration of 100 nM vasoactive intestinal peptide potently enhanced the decrease in Isc evoked by 20 µM troglitazone (21.1 ± 1.63 µA/cm2). The cyclic AMP contents of rat duodenal mucosa incubated with and without troglitazone (20 µM) for 50 min were 3.2 ± 0.25 and 5.8 ± 0.46 pmol/mg protein, respectively (P < .01). These results indicate that the ionic basis for the decrease in Isc that is induced by troglitazone may be inhibition of electrogenic bicarbonate secretion. The alteration of intestinal ion transport by troglitazone could cause edema.


0022-3565/99/2903-1080$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Eur Heart JHome page
E. Erdmann and R. G. Wilcox
Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure
Eur. Heart J., January 1, 2008; 29(1): 12 - 20.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
H. Zhang, A. Zhang, D. E. Kohan, R. D. Nelson, F. J. Gonzalez, and T. Yang
Collecting duct-specific deletion of peroxisome proliferator-activated receptor {gamma} blocks thiazolidinedione-induced fluid retention
PNAS, June 28, 2005; 102(26): 9406 - 9411.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. W. Nesto, D. Bell, R. O. Bonow, V. Fonseca, S. M. Grundy, E. S. Horton, M. Le Winter, D. Porte, C. F. Semenkovich, S. Smith, et al.
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association
Circulation, December 9, 2003; 108(23): 2941 - 2948.
[Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.